These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms. Kobayashi M; Mori A; Onozawa M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Kanaya M; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T Ann Hematol; 2023 Apr; 102(4):819-827. PubMed ID: 36862167 [TBL] [Abstract][Full Text] [Related]
3. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554 [TBL] [Abstract][Full Text] [Related]
4. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations. Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557 [TBL] [Abstract][Full Text] [Related]
5. Vaccination for SARS-CoV-2 in Hematological Patients. Riccardi N; Falcone M; Yahav D Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303 [TBL] [Abstract][Full Text] [Related]
6. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents. Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G; J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928 [TBL] [Abstract][Full Text] [Related]
7. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A; Front Immunol; 2022; 13():868915. PubMed ID: 35432335 [TBL] [Abstract][Full Text] [Related]
8. Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV. El Moussaoui M; Desmecht S; Lambert N; Maes N; Braghini J; Marechal N; Quintana C; Briquet K; Gofflot S; Toussaint F; Hayette MP; Vermeersch P; Lutteri L; Grégoire C; Beguin Y; Rahmouni S; Moutschen M; Desmecht D; Darcis G Viruses; 2023 Jun; 15(7):. PubMed ID: 37515123 [TBL] [Abstract][Full Text] [Related]
9. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose. Ruggieri S; Aiello A; Tortorella C; Navarra A; Vanini V; Meschi S; Lapa D; Haggiag S; Prosperini L; Cuzzi G; Salmi A; Quartuccio ME; Altera AMG; Garbuglia AR; Ascoli Bartoli T; Galgani S; Notari S; Agrati C; Puro V; Nicastri E; Gasperini C; Goletti D Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239872 [TBL] [Abstract][Full Text] [Related]
10. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E Front Immunol; 2022; 13():907615. PubMed ID: 35812459 [TBL] [Abstract][Full Text] [Related]
11. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D Front Immunol; 2022; 13():846753. PubMed ID: 35309297 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis. Uaprasert N; Pitakkitnukun P; Tangcheewinsirikul N; Chiasakul T; Rojnuckarin P Blood Cancer J; 2022 Dec; 12(12):173. PubMed ID: 36550105 [TBL] [Abstract][Full Text] [Related]
13. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation. Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E Front Immunol; 2023; 14():1174289. PubMed ID: 37207199 [TBL] [Abstract][Full Text] [Related]
14. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899 [TBL] [Abstract][Full Text] [Related]
15. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
16. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms. Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. Ruether DF; Schaub GM; Duengelhoef PM; Haag F; Brehm TT; Fathi A; Wehmeyer M; Jahnke-Triankowski J; Mayer L; Hoffmann A; Fischer L; Addo MM; Lütgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M Clin Gastroenterol Hepatol; 2022 Jan; 20(1):162-172.e9. PubMed ID: 34509643 [TBL] [Abstract][Full Text] [Related]
18. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients. Harberts A; Schaub GM; Ruether DF; Duengelhoef PM; Brehm TT; Karsten H; Fathi A; Jahnke-Triankowski J; Fischer L; Addo MM; Haag F; Luetgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2558-2566.e5. PubMed ID: 35850415 [TBL] [Abstract][Full Text] [Related]
19. Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach. Montesi G; Augello M; Polvere J; Marchetti G; Medaglini D; Ciabattini A J Transl Med; 2024 May; 22(1):432. PubMed ID: 38715088 [TBL] [Abstract][Full Text] [Related]
20. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days. Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R Front Immunol; 2021; 12():726960. PubMed ID: 34671348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]